Skip to main content

Table 2 Risk factors for overall survival in 4496 patients with limited-disease small-cell lung cancer

From: Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study

  Unadjusted RR Adjusted RR
  RR (95% CI) P-value RR (95% CI) P-value
Age, years (≥65 vs. < 65) 1.15 (1.11–1.20) <  0.0001 1.18 (1.12–1.22) <  0.0001
Sex (male vs. female) 1.06 (1–1.12) 0.07 1.04 (0.98–1.10) 0.22
HBP (HBP vs. normal) 0.96 (0.93–1.00) 0.05 1.02 (0.98–1.06) 0.45
DM (DM vs. normal) 0.97 (0.93–1.02) 0.22 1.04 (1.00–1.09) 0.06
Hypercholesterolemia (No vs. yes) 1.28 (1.23–1.33) <  0.0001 1.32 (1.27–1.37) < 0.0001
Definite CCRT (IP-CCRT vs. EP-CCRT) 1.61 (1.30–2.04) < 0.0001 1.49 (1.18–1.92) < 0.0001
  1. RR, relative risk; CI, confidence interval; HBP, hypertension; DM, diabetes mellitus; CCRT, concurrent chemoradiotherapy; IP, irinotecan/platinum; EP, etoposide/platinum